other material
confidence high
sentiment positive
materiality 0.80
Aldeyra Phase 2 ADX-629 in chronic cough meets primary safety endpoint; cough frequency significantly reduced vs placebo
Aldeyra Therapeutics, Inc.
- Awake cough frequency reduced vs placebo (P=0.01); 24-hr cough frequency (P=0.001).
- ADX-629 well tolerated; no serious adverse events or discontinuations reported.
- 51 patients enrolled, all completed both treatment periods in crossover design.
- Improvement in LDL and HDL levels observed consistent with prior trials.
- Company to discuss results with regulators; Phase 2 trials in atopic dermatitis and other indications expected 2H 2023.